Lu, Y. Et Al. 2019. Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study. European-Society-for-Medical-Oncology (ESMO) Asia Congress , (Singapore, Singapore).

Lu, Y., Malwinder, S. S., Azim, H., Eralp, Y., Im, S., Yap, Y. S., ... Alfaro, T. D.(2019). Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study . European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore

Lu, Y-S. Et Al. "Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study," European-Society-for-Medical-Oncology (ESMO) Asia Congress, Singapore, Singapore, 2019

Lu, Y-S. Et Al. "Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study." European-Society-for-Medical-Oncology (ESMO) Asia Congress , Singapore, Singapore, 2019

Lu, Y. Et Al. (2019) . "Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study." European-Society-for-Medical-Oncology (ESMO) Asia Congress , Singapore, Singapore.

@conferencepaper{conferencepaper, author={Y-S. Lu Et Al. }, title={Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2-inoperable locally advanced breast cancer (ABC): RIGHT choice study}, congress name={European-Society-for-Medical-Oncology (ESMO) Asia Congress}, city={Singapore}, country={Singapore}, year={2019}}